$162,050
median · per year, annualized USD
$123,300
median · per year, annualized USD
AI Scientist/Senior, Clinical & Molecular Genomics Modeling, BRAID
Lead or Senior Scientist - Genome Editing, Genomics, Biotechnology (Shengdar Q. Tsai Lab)
Principal Clinical Molecular Geneticist
Senior Research Scientist - Genomics and Infectious Diseases
Clinical Geneticist
Principal Scientist (m/f/d) Genomic Technologies, Human Genetics and Genomics
Computational Genomics Senior Research Scientist
Physician - Geneticist
Scientist 3, Single Cell & Functional Genomics
Principal Scientist, Discovery BioSciences Genomics, Oncology TRC
Associate Director, Drug Safety
Drug Safety Associate III
Drug Safety Associate II
Senior Specialist I, Patient Safety & Pharmacovigilance (Clinical Trial Safety Operations)
Associate Specialist Drug Safety
Specialist I, Patient Safety and Pharmacovigilance Operations
| Company | Median | Roles |
|---|---|---|
| SJ St. Jude Children's Research Hospital | $120,640 | 3 |
Roche
|
$179,400 | 2 |
Bristol Myers Squibb
|
$162,950 | 2 |
| PA Parsons | $158,725 | 2 |
Vertex Pharmaceuticals
|
$151,200 | 2 |
| TM Tufts Medicine | $212,562 | 1 |
Endeavor Health
|
$192,000 | 1 |
Abbott
|
$170,000 | 1 |
| Company | Median | Roles |
|---|---|---|
Exelixis
|
$142,000 | 2 |
Corcept Therapeutics
|
$98,375 | 2 |
Iambic Therapeutics, Inc
|
$184,500 | 1 |
MSD
|
$92,550 | 1 |
| Location | Median | Roles |
|---|---|---|
| San Francisco | $147,700 | 3 |
The median for Geneticist is $162,050 per year (typically $140,575–$174,542), versus $123,300 for Pharmacovigilance ($99,500–$149,875). That puts Geneticist about 31% ahead at the median.
Both figures are computed live from active listings on JobsRadar and normalized to annualized USD, so Geneticist and Pharmacovigilance are compared on equal terms regardless of the currency each role was originally posted in. Only roles that publish a salary range feed the medians; numbers refresh every few hours as new roles post and older ones close, so this comparison reflects the market right now rather than a fixed survey. Use it as a directional benchmark when weighing one path against the other.